Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps.

ABSTRACT: The purpose of this study was to evaluate the efficacy of intravitreal aflibercept for active polypoidal choroidal vasculopathy (PCV) without active polyps and to identify prognostic factors. We enrolled 40 eyes from 40 patients who manifested PCV with exudation but without active polyps after prior treatment with photodynamic therapy (PDT) and/or anti-vascular endothelial growth factor (VEGF) other than aflibercept. Participants were initially given three consecutive intravitreal injections of aflibercept at 1-month intervals, followed by injections every 2 months in the maintenance phase. Spectral-domain optical coherence tomographic and indocyanine green angiographic features were assessed to determine associations between anatomical parameters and visual outcomes 14?months later. Mean visual acuity improved from 61.5?±?11.1 letters at baseline to 68.1?±?13.6 letters at 14 months (P?=?0.001). Better vision and a smaller branching vascular network at baseline and 1 month after three monthly injections (visit 4) were associated with better final vision (P?

SUBMITTER: Lee SE 

PROVIDER: S-EPMC6365522 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature